FSD Pharma: Synthetic Compounds for Unmet Medical Needs
Addressing unmet medical needs
FSD Pharma is focused on developing FDA approved synthetic compounds that address unmet medical needs. In addition, they have a team of experienced healthcare and pharmaceutical executives and an advisory board of leading researchers.
FSD now listed on the NASDAQ
On Monday January 9, 2020 FSD experienced a significant milestone as they commenced trading on the Nasdaq capital market.
The company’s Class B subordinate voting shares started trading on the Nasdaq market under the symbol “HUGE”.
“The listing of our shares on the Nasdaq capital market is a momentous moment and represents a paradigm shift in the outlook of FSD Pharma,” says Dr. Raza Bokhari, Executive Co-Chairman and CEO on their press release.
Also, he adds that a Nasdaq listing elevates the company’s corporate profile to institutional investors.
More about FSD
Overall, FSD Pharma is a specialty, biotech pharmaceutical R&D company. Above all, they focus on developing FDA approved synthetic compounds targeting the endocannabinoid system of the human body.
Ultimately, FSD wants to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract and the musculoskeletal system.
In addition, through its acquisition of Prismic Pharmaceuticals in 2019, FSD is making an effort to help address the opioid crisis. They do this by developing opioid-sparing prescription drugs utilizing the micronized formulations of palmitoylethanolamide (PEA). In fact, they intend to initiate the first phase of first-in-human safety and tolerability trials for its lead candidate, PP 101 micro-PEA in the first quarter of 2020.
For more information on FSD Pharma (HUGE:CSE, HUGE: NASDAQ) please fill out the form below.